Magnetic Resonance Imaging + Biospecimen Collection + Computed Tomography + Echocardiography Test + NIVOLUMAB + IPILIMUMAB for carcinoma, giant cell

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 15 Jul 2016: Trial registered, NCT02834013
  2. 30 Jan 2017: Trial started, NCT02834013

The trials

NCT02834013: Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

State
Under way
Phase
Phase 2
People
798 taking part
Started
30 Jan 2017
Primary completion
1 May 2026
Arms
Arm I (nivolumab, ipilimumab)
Results
None posted
  1. 15 Jul 2016: Trial registered
  2. 30 Jan 2017: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.